Alferon LDO (low dose interferon alfa-n3) / AIM ImmunoTech - LARVOL DELTA

AIM ImmunoTech announces completion of third-party clinical trial using Ampligen in combination with other therapies as adjuvant treatment of peritoneal surface malignancies (Yahoo Finance) - "AIM ImmunoTech Inc...today announced posting by the University of Pittsburgh Medical Center (UPMC) on January 28, 2020 via ClinicalTrials.gov of completion of an independent, third-party clinical trial to evaluate the safety and activity of a triple combination (chemokine modulatory regimen or CKM) of celecoxib, interferon alfa (IFN), and Ampligen (rintatolimod), given with a dendritic cell (DC) vaccine, as a potential treatment for metastatic peritoneal surface malignancies after standard of care surgery."

Trial completion